The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

• Robert J. Moots ,

  * E-mail: R.J.Moots@liverpool.ac.uk

  Affiliation Aintree University Hospital, University of Liverpool, Liverpool, United Kingdom

  ⨯
• Ricardo M. Xavier,

  Affiliation Hospital de Clinicas, Porto Alegre, Brazil

  ⨯
• Chi Chiu Mok,

  Affiliation Tuen Mun Hospital, Hong Kong, People’s Republic of China

  ⨯
• Mahboob U. Rahman,

  Current address: Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

  Affiliation Pfizer, Collegeville, Pennsylvania, United States of America

  ⨯
• Wen-Chan Tsai,

  Affiliation Kaohsiung Medical University, Kaohsiung City, Taiwan

  ⨯
• Mustafa H. Al-Maini,

  Affiliation Mafraq Hospital, Abu Dhabi, United Arab Emirates

  ⨯
• Karel Pavelka,

  Affiliation Institute of Rheumatology, Prague, Czech Republic

  ⨯
• Ehab Mahgoub,

  Affiliation Pfizer, Collegeville, Pennsylvania, United States of America

  ⨯
• Sameer Kotak,

  Current address: Independent Consultant, Parsippany, New Jersey, United States of America

  Affiliation Pfizer, Collegeville, Pennsylvania, United States of America

  ⨯
• Joan Korth-Bradley,

  Affiliation Pfizer, Collegeville, Pennsylvania, United States of America

  ⨯
• Ron Pedersen,

  Affiliation Pfizer, Collegeville, Pennsylvania, United States of America

  ⨯
• Linda Mele,

  Affiliation Pfizer, Collegeville, Pennsylvania, United States of America

  ⨯
• Qi Shen,

  Affiliation Pfizer, Collegeville, Pennsylvania, United States of America

  ⨯
• Bonnie Vlahos

  Affiliation Pfizer, Collegeville, Pennsylvania, United States of America

  ⨯